TY  - GEN
AU  - Colombel,Jean-Frédéric
AU  - Sands,Bruce E
AU  - Rutgeerts,Paul
AU  - Sandborn,William
AU  - Danese,Silvio
AU  - D'Haens,Geert
AU  - Panaccione,Remo
AU  - Loftus,Edward V
AU  - Sankoh,Serap
AU  - Fox,Irving
AU  - Parikh,Asit
AU  - Milch,Catherine
AU  - Abhyankar,Brihad
AU  - Feagan,Brian G
TI  - The safety of vedolizumab for ulcerative colitis and Crohn's disease
SN  - 1468-3288
PY  - 2017///0710
KW  - Adrenal Cortex Hormones
KW  - therapeutic use
KW  - Adult
KW  - Age Factors
KW  - Antibodies, Monoclonal, Humanized
KW  - adverse effects
KW  - Antibodies, Neutralizing
KW  - blood
KW  - Chemical and Drug Induced Liver Injury
KW  - epidemiology
KW  - Clostridium Infections
KW  - Colitis, Ulcerative
KW  - drug therapy
KW  - Crohn Disease
KW  - Female
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Incidence
KW  - Infusions, Intravenous
KW  - Leukoencephalopathy, Progressive Multifocal
KW  - Male
KW  - Middle Aged
KW  - Narcotics
KW  - Neoplasms
KW  - Randomized Controlled Trials as Topic
KW  - Risk Factors
KW  - Sepsis
KW  - Treatment Failure
KW  - Tuberculosis
KW  - Tumor Necrosis Factor-alpha
KW  - antagonists & inhibitors
KW  - Young Adult
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1136/gutjnl-2015-311079
ER  -